BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  American Journal of Cancer Research

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJROBP.2016.06.2028PMID 27429848PMCID PMC4937737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bortezomib in the treatment of mantle cell lymphoma.

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Supplemental Material to :

  2014cited by this paper
• Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4

  2014cited by this paper
• Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

  2014cited by this paper
• Using BRAFV600E as a marker of autophagy dependence in pediatric brain tumors

  2014cited by this paper
• Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

  2014cited by this paper
• Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells.

  2014cited by this paper
• Autophagy proteins regulate ERK phosphorylation

  2013cited by this paper
• Epigenetic and genetic features of 24 colon cancer cell lines

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

  2013cited by this paper
• Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.

  2013cited by this paper
• Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: relationship with cytosolic calcium mobilization.

  2012cited by this paper
• Autophagy contributes to resistance of tumor cells to ionizing radiation.

  2011cited by this paper
• Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

  2011cited by this paper
• Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1.

  2011cited by this paper
• Apoptosis and beyond: cytometry in studies of programmed cell death.

  2011cited by this paper
• Upregulation of human autophagy-initiation kinase ULK1 by tumor suppressor p53 contributes to DNA-damage-induced cell death

  2011cited by this paper
• Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

  2011cited by this paper
• Reciprocal influence of the p53 and the hypoxic pathways

  2011cited by this paper
• A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum

  2011cited by this paper
• The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

  2011cited by this paper
• Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells*

  2011cited by this paper
• Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

  2010cited by this paper
• Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models

  2009cited by this paper
• Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

  2008cited by this paper
• The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family

  2008cited by this paper
• Autophagy in the pathogenesis of disease.

  2008cited by this paper
• Tumor suppression by autophagy through the management of metabolic stress.

  2008cited by this paper
• p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter

  2008cited by this paper
• Bcl-2 family members: dual regulators of apoptosis and autophagy.

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Tumor suppression by autophagy through the management of metabolic stress

  2008cited by this paper
• Autophagy fights disease through cellular self-digestion

  2008cited by this paper
• Bcl-2 family members: Dual regulators of apoptosis and autophagy

  2008cited by this paper
• Autophagy delays apoptotic death in breast cancer cells following DNA damage

  2007cited by this paper
• The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment

  2007cited by this paper
• Bortezomib for the Treatment of Mantle Cell Lymphoma

  2007cited by this paper
• Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation.

  2007cited by this paper
• Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis*

  2006cited by this paper
• Cell death in the nervous system

  2006cited by this paper
• Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

  2006cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005influential reference
• Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.

  2005cited by this paper
• A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer

  2005cited by this paper
• A phase II study of bortezomib in the treatment of metastatic malignant melanoma

  2005cited by this paper
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  2004cited by this paper
• p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3

  2002cited by this paper
• Proteasome inhibitors differentially affect heat shock protein response in cancer cells.

  2001cited by this paper
• LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

  2000cited by this paper
• Activation of the cell death program by inhibition of proteasome function.

  1997cited by this paper
• Cancer statistics

  1989cited by this paper
• 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes.

  1982cited by this paper

• Blockage of Autophagy for Cancer Therapy: A Comprehensive Review

  2024cites this paper
• Autophagy and Cell Death: Antitumor Drugs Targeting Autophagy

  2023cites this paper
• STAT3 regulates 5‐Fu resistance in human colorectal cancer cells by promoting Mcl‐1–dependent cytoprotective autophagy

  2023cites this paper
• Spin column-based peptide fractionation alternatives for streamlined tandem mass tag (SL-TMT) sample processing.

  2023cites this paper
• Simultaneous proteasome and autophagy inhibition synergistically enhances cytotoxicity of doxorubicin in breast cancer cells

  2022cites this paper
• Combination of an Autophagy Inducer and an Autophagy Inhibitor: A Smarter Strategy Emerging in Cancer Therapy

  2020cites this paper
• Dual Roles of Autophagy and Their Potential Drugs for Improving Cancer Therapeutics

  2020cites this paper
• Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Autophagy and Cell Death: Antitumor Drugs Targeting Autophagy

  2019cites this paper
• Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling and Downregulation of IL-6, TNF-α, and HMGB1

  2018cites this paper
• Mcl‐1 targeting could be an intriguing perspective to cure cancer

  2018cites this paper
• Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

  2018cites this paper
• Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI

  2018cites this paper
• Development of noninvasive biomarkers of response to proteasome inhibitor therapy (ixazomib) by imaging disrupted protein homeostasis in mouse models of solid tumors

  2017cites this paper
• YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells

  2017cites this paper
• The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent

  2017cites this paper